S-1/A: Nuwellis Eyes $4.3 Million in New Offering to Bolster Working Capital

Nuwellis, Inc. aims to raise approximately $4.3 million through a public offering of common stock and warrants to fund working capital and commercialization efforts.

Summary

• Nuwellis, Inc. is undertaking a public offering to sell up to 10,204,081 shares of common stock and an equal number of common stock purchase warrants.
• The assumed combined public offering price is $0.49 per share and common warrant, based on the closing price of the common stock on March 8, 2024.
• The company is also offering pre-funded warrants to certain purchasers who would otherwise exceed ownership limits.
• Each pre-funded warrant is sold with a common warrant, with the price equal to the combined price minus $0.0001.
• The offering will terminate on April 30, 2024, and there is no minimum offering requirement.
• The company estimates net proceeds of approximately $4.3 million, after deducting placement agent fees and offering expenses.
• These proceeds are intended for working capital and general corporate purposes, including commercialization investments.
• Roth Capital Partners, LLC is acting as the exclusive placement agent for the offering, receiving a cash fee of 7.0% of the gross proceeds.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the capital raise is necessary for the company's operations, it also presents risks of dilution and potential delisting. The company's future prospects depend on the successful deployment of the raised capital.

Positives

• The offering aims to strengthen the company's financial position by providing additional working capital.
• Proceeds will support continued investments in commercialization efforts, potentially driving revenue growth.
• The offering structure includes pre-funded warrants, providing flexibility for certain investors.
• The engagement of Roth Capital Partners as placement agent could facilitate successful placement of the securities.

Negatives

• The offering is on a 'reasonable best efforts' basis, with no guarantee of raising the full $4.3 million.
• Investors will experience immediate dilution in the net tangible book value per share.
• The company has broad discretion in using the net proceeds, which may not be used effectively.
• There is no established trading market for the warrants, limiting their liquidity.
• The company's common stock is subject to delisting from the Nasdaq Capital Market if it does not regain compliance with the minimum bid price requirement.

Risks

• The company may not raise sufficient capital to implement its business plans and satisfy current obligations.
• The market price of the common stock could decrease due to the offering.
• Nasdaq may delist the company's common stock, limiting investors' ability to make transactions.
• The company may not receive any additional funds upon the exercise of the common warrants.
• The common warrants are speculative in nature and may not be profitable for holders to exercise.

Future Outlook

The company intends to use the net proceeds of this offering for working capital and general corporate purposes, including for continued investments in our commercialization efforts.

Industry Context

This announcement reflects a common strategy for small-cap companies in the medical device sector to raise capital for ongoing operations and product development. The success of the offering will be crucial for Nuwellis to continue its commercialization efforts and fund the development of its CRRT device.

Comparison to Industry Standards

• Comparable companies in the medical device space, such as SeaStar Medical Holding Corporation, also rely on capital markets to fund research and development and commercialization activities.
• The offering structure, including common stock and warrants, is a typical approach for companies seeking to attract investors while managing potential dilution.
• The placement agent fee of 7.0% is within the typical range for similar offerings.

Stakeholder Impact

• Shareholders will experience dilution as a result of the offering.
• Employees may benefit from the increased financial stability and commercialization efforts.
• Customers may benefit from the development and commercialization of new products.
• Suppliers and creditors may benefit from the company's improved financial position.

Next Steps

• The company will continue actively monitoring the closing bid price for its common stock.
• The company will consider available options to resolve the deficiency and regain compliance with the Minimum Bid Price Requirement.
• The company intends to submit an IDE with the FDA in the third quarter of 2024 for its Vivian CRRT device.
• The company expects U.S. commercialization of the Vivian CRRT device in the fourth quarter of 2025.

Key Dates

Keywords

common stock, warrants, offering, Nuwellis, pre-funded warrants, capital raise, placement agent, Roth Capital Partners, dilution, working capital